Citations

Clear

13 citation(s) found for "Goodman, Michael".

Clopidogrel Pharmacogenetics
Pereira, Naveen L. , Rihal, Charanjit S. , So, Derek , Rosenberg, Yves , Lennon, Ryan J. , Mathew, Verghese, Weinshilboum, Richard M., Wang, Liewei , Baudhuin, Linnea M. , Hasan, Ahmed , Iturriaga, Erin , Fu, Yi-Ping, Geller, Nancy L. , Bailey, Kent R. , Farkouh, Michael E. , Rihal, Charanjit S. , Lennon, Ryan J. , Goodman, Shaun G. , Lerman, Amir

Mayo Clinic

Circulation: Cardiovascular Interventions | April 11, 2019 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/circinterventions.119.007811 | PMID 30998396 Get It

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial.
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Bhatt, Deepak L. , Moliterno, David J. , Cannon, Christopher P. , Tanguay, Jean-François, Granger, Christopher B. , Holmes, David R. , Faxon, David P., Bhatt, Deepak L , Granger, Christopher B , Angiolillo, Dominick J. , Goodman, Shaun G. , Eikelboom, John W. , Price, Matthew J. , Tanguay, Jean‐François , Mauri, Laura , Gibson, C. Michael

Mayo Clinic

Circulation | September 16, 2018 | Volume: 138 | Issue: 5 | Pages: 527-536

10.1161/circulationaha.118.034722 | PMID 30571525 Get It

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice. In 2016, an updated opinion of selected experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention was reported. After the 2016 North American consensus statement on the management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, results of pivotal clinical trials assessing the type of oral anticoagulant agent and the duration of antiplatelet treatment have been published. On the basis of these results, this focused update on the antithrombotic management of patients with atrial fibrillation undergoing percutaneous coronary intervention recommends that a non–vitamin K antagonist oral anticoagulant be preferred over a vitamin K antagonist as the oral anticoagulant of choice. Moreover, a double-therapy regimen (oral anticoagulant plus single antiplatelet therapy with a P2Y 12 inhibitor) by the time of hospital discharge should be considered for most patients, whereas extending the use of aspirin beyond hospital discharge (ie, triple therapy) should be considered only for selected patients at high ischemic/thrombotic and low bleeding risks and for a limited period of time. The present document provides a focused updated on the rationale for the new expert consensus–derived recommendations on the antithrombotic management of patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention.
Cortical Tuber Count: A Biomarker Indicating Neurologic Severity of Tuberous Sclerosis Complex
Goodman, Michael , Lamm, Steven H. , Engel, Arnold, Shepherd, C. W., Houser, O. Wayne, Gómez, Manuel R.

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 12 | Issue: 2 | Pages: 85-90

10.1177/088307389701200203 | PMID 9075016 Get It

The relationship between the number of cortical tubers observed by magnetic resonance imaging (MRI) and the severity of cerebral dysfunction of tuberous sclerosis patients has been examined in a meta-analysis of the published literature. The literature review has identified five independent studies for examining the association. These studies consistently reveal that the cortical tuber count detected on MRI scans is increased among those with more severe cerebral disease. Severity of the cerebral dysfunction is measured by the seizure status and its control and by the developmental status and the level of mental retardation. Meta-analysis demonstrates that within a study population, the MRI-detected cortical tuber count is six times more likely to be above the median count for tuberous sclerosis patients with severe cerebral dysfunction (poor seizure control or moderate-severe retardation or both) than more mildly affected tuberous sclerosis patients. Similarly, across studies, moderately to severely affected patients are five times more likely to have greater than seven MRI-detected cortical tubers than those more mildly affected. These associations are both statistically significant and strong. The cortical tuber count is a biomarker that reasonably predicts the severity of cerebral dysfunction of tuberous sclerosis. Cortical tubers of tuberous sclerosis form in the early gestational period. The embryologic disruption determining the clinical severity of the cortical dysfunction of tuberous sclerosis is set in the early gestational period. (J Child Neurol 1997;12:85-90).